Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
By Route of Administration: Parenteral dominates, Oral growing fastest Parenteral (subcutaneous injection) delivery held the dominant route of administration position in 2025, reflecting that all high-dose, high-efficacy GLP-1 formulations currently approved for obesity management require injection for the delivery of drug quantities sufficient to achieve therapeutic plasma concentrations
2E, F, H)
Proc Natl Acad Sci 101:37803785
In the absence of head-to-head trials, we also found high certainty evidence for notable differences between SGLT-2 inhibitors and GLP-1 receptor agonists
US$ 21.24
US$ 20.12
US$ 27.56
US$ 26.35
US$ 29.29
US$ 22.89
US$ 22.41
